UNSPSC 51203403: Mercaptopurine

This classification denotes a purine antagonist and immunosuppressant with the molecular formula C5H4N4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E7WED276I5, chemically known as 1,7-dihydro-6h-purine-6-thione but more generally known as 6-mercaptopurine monohydrate, which bears US NIH Compound Identifier 667490. European Medicines Agency schedules Mercaptopurine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12149MIG.

UNSPSC 51203403 Mercaptopurine is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity under this code shows little direct relevance. The single opportunity nominally tagged to mercaptopurine — Seminole County's IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) — is unrelated to mercaptopurine; the county is procuring emergency opioid antagonists and drug disposal equipment for community health support, not a cancer chemotherapy agent. State and local governments acquire mercaptopurine primarily through multi-agency cooperative purchasing vehicles and statewide pharmaceutical frameworks rather than as a standalone bid line item. When mercaptopurine does move through state procurement channels, it appears as one line item within broad generic pharmaceutical RFPs administered by multistate purchasing consortia serving health departments, corrections facilities, and public health clinics.

The three remaining opportunities in the recent window represent the broader pharmaceutical and medical supply procurement environment in which this Commodity code operates. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026), serving state and local government facilities across multiple states including Oregon and Minnesota; the Texas Health and Human Services Commission posted an RFI exploring direct-to-manufacturer prescription programs (HHS0017013, April 3, 2026); and the City of Tampa solicited medical and first aid supplies for its Fire Department Rescue Division (26P00145, due March 13, 2026, $700,000 contract with a 5% bid discount for certified Small Local Business Enterprises). Recent activity clusters in cooperative purchasing frameworks and multi-state consortia rather than individual agency purchases, indicating that vendors pursuing mercaptopurine sales to state and local buyers should target MMCAP, state health and human services procurement offices, and multistate pharmaceutical contracting vehicles where the product can be positioned alongside comparable generics. Geographic concentration in recent opportunities appears in Minnesota, Texas, and Florida, though the code itself generates sparse standalone solicitation activity.